Serum α-klotho levels are not informative for the evaluation of GH secretion in short children.

Heba Elsedfy1, Cristina Meazza2, Giorgio Radetti3, Randa I. Khalaf1, Sara Pagani2, Nicodemo Sessa4, Riccardo Albertini1, Anna Maria De Stefano5, Antonella Navarra5, Fiorenzo Lupi5, Mohamed El Kholy1, Mauro Bozolla2.

1 Paediatrics Department, Ain Shams University, Cairo, Egypt; 2 Internal Medicine and Therapeutics Department, Paediatric and Adolescent Unit, University of Pavia, Fondazione IRCCS Policlinico San Matteo Pavia, Italy; 3 Marienklinik, Bolzano, Italy; 4 Laboratory of Clinical Chemistry Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; 5 IRCCS Fondazione Salvatore Maugeri, Pavia, Italy; 6 Ospedale Regionale di Bolzano, Bolzano, Italy.

The authors have nothing to disclose.

OBJECTIVES

α-klotho is a transmembrane protein which can be cleaved and act as a circulating hormone. Since low α-klotho levels were found in organic growth hormone deficiency (GHD) and high levels in acromegaly, an interaction between α-klotho, GH and linear growth has been suggested. We investigated the role of α-klotho protein as a reliable marker of GH secretion in short children and the factors influencing its secretion. For this purpose, we used the pegvisomant-primed GH stimulation test, since pegvisomant acts as enhancer of GH secretion.

METHODS

We enrolled 20 Egyptian short children with reduced GH secretion (GH peak <10 ng/ml) after two pharmacological stimuli (clonidine and insulin tolerance test) and 20 subjects with normal GH secretion. Chronological age was 9.48±2.84 and 10.49±1.98 years, BMI -0.96±0.90 and -1.26±1.33 SDS and height -0.49±0.63 and -3.25±0.58 SDS in GHD and ISS, respectively. Then, pegvisomant was injected subcutaneously and after three days a GH stimulation test (insulin tolerance test) was performed. The baseline samples obtained before and after pegvisomant were used for measuring IGF-I and α-klotho. α-klotho levels were measured by a commercially available ELISA assay; IGF-I and GH levels were determined by a chemiluminescent assay which has no cross-reaction with pegvisomant.

RESULTS

IGF-I serum levels were lower in GHD compared to ISS (125±110 vs 188±91 ng/ml) (Fig. 1) although the difference was not statistically significant (p=0.059). Furthermore, α-klotho basal levels were not significantly different between GHD and ISS children (1397±697 vs 1760±975 pg/ml; p=0.1) (Fig. 2). After pegvisomant priming, a significant reduction of IGF-I was observed in the GHD group (90±83 ng/ml; p<0.002) as well as in the ISS group (107±59 ng/ml; p<0.001) (Fig. 1). The delta of IGF-I was greater in the ISS than in the GHD group (84.3±59.9 vs 35.7±41.8; p<0.03). α-klotho significantly decreased also both in the GHD group (1069±516 pg/ml; p<0.002) and in the ISS subjects (1393±728 pg/ml; p<0.001) (Fig. 2), but the delta of α-klotho (395±422 vs 570±331; p=0.1) and the post pegvisomant values were not different between the two groups. Roc analysis could not identify a threshold to differentiate GHD from non-GHD children (Fig. 3).

α-klotho basal levels significantly correlated with IGF-I levels in GHD (before priming R=0.4173, p=0.05; after priming R=0.5604, p=0.0298) and ISS subjects (before priming R=0.7098, p=0.0002; after priming R=0.5428, p=0.009).

In the multiple regression analysis, basal IGF-I was the only factor influencing basal α-klotho (p=0.002).

CONCLUSIONS

In conclusion, IGF-I and the nutritional status have a role in the regulation of circulating α-klotho. Therefore, α-klotho is a good marker of the IGF-I status but not a reliable one for the evaluation of GH secretion in children.

References